1. Memon, N, Weinberger, BI, Hegyi, T, Aleksunes, LM. Inherited disorders of bilirubin clearance. Pediatr Res. 2016;79(3): 78–86.
Google Scholar | Crossref2. Wagner, K-H, Shiels, RG, Lang, CA, Seyed, KN, Bulmer, AC. Diagnostic criteria and contributors to Gilbert’s syndrome. Crit Rev Clin Lab Sci. 2018;55(2):129–139.
Google Scholar | Crossref | Medline3. Horsfall, LJ, Rait, G, Walters, K, et al. Serum bilirubin and risk of respiratory disease and death. JAMA. 2011;305(7):691–697.
Google Scholar | Crossref | Medline4. Copur, B, Yilmaz, N, Topcuoglu, C, et al. Relationship between elevated bilirubin level and subclinical atherosclerosis as well as oxidative stress in Gilbert syndrome. Gastroenterol Hepatol Bed Bench. 2020;13(2):133–140.
Google Scholar | Medline5. Dani, C, Poggi, C, Pratesi, S. Bilirubin and oxidative stress in term and preterm infants. Free Radic Res. 2019;53:2–7.
Google Scholar | Crossref | Medline6. Vítek, L, Novotny, L, Sperl, M, Holaj, R, Spácil, J. The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc Dis. 2006;21:408–414.
Google Scholar | Crossref | Medline | ISI7. Muccini, C, Galli, L, Poli, A, et al. Brief report: hyperbilirubinemia is associated with decreased risk of carotid atherosclerosis in HIV-infected patients on virological suppression. J Acquir Immune Defic Syndr. 2018;79:617–623.
Google Scholar | Crossref | Medline8. Novotný, L, Vítek, L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med. 2003;228:568–571.
Google Scholar | SAGE Journals | ISI9. Victor, VM, Rocha, M, Sola, E, Banuls, C, Garcia-Malpartida, K, Hernandez-Mijares, A. Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharmaceut Des. 2009;15:2988–3002.
Google Scholar | Crossref | Medline | ISI10. Watson, T, Goon, PK, Lip, GY. Endothelial progenitor cells, endothelial dysfunction, inflammation and oxidative stress in hypertension. Antioxidants Redox Signal. 2008;10:1079–1088.
Google Scholar | Crossref | Medline11. Incalza, MA, D’Oria, R, Natalicchioa, A, Perrini, S, Laviola, L, Giorgino, F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vasc Pharmacol. 2018;100:1–19.
Google Scholar | Crossref | Medline12. Balamir, I, Ates, I, Topcuoglu, C, Turhan, T. Association of endocan,ischemia-modified albumin and hsCRP levels with endothelial dysfunction in type 2 diabetes mellitus. Angiology. 2018;69:609–616.
Google Scholar | SAGE Journals | ISI13. Bessa, J, Albino-Teixeira, A, Reina-Couto, M, Sousa, T. Endocan: a novel biomarker for risk stratification, prognosis and therapeutic monitoring in human cardiovascular and renal diseases. Clin Chim Acta. 2020;509:310–35.
Google Scholar | Crossref | Medline14. Qiu, CR, Fu, Ç, Sui, J, et al. Serum endothelial cell–specific molecule 1 (endocan) levels in patients with acute myocardial infarction and its clinical significance: a pilot study. Angiology. 2017;68:354–359.
Google Scholar | SAGE Journals | ISI15. Yildiz, A, Oflaz, H, Pusuroglu, H, et al. Left ventricular hypertrophy and endothelial dysfunction in chronic hemodialysis patients. Am J Kidney Dis 2003;41:616–623.
Google Scholar | Crossref | Medline | ISI16. Koppula, S, Kumar, H, Kim, IS, Choi, DK. Reactive oxygen species and inhibitors of inflammatory enzymes, NADPH oxidase, and iNOS in experimental models of Parkinson’s disease. Mediat Inflamm. 2012;2012:823902.
Google Scholar | Crossref | Medline17. Kleniewska, P, Piechota, A, Skibska, B, Gorąca, A. The NADPH oxidase family and its inhibitors. Arch Immunol Ther Exp. 2012;60:277–294.
Google Scholar | Crossref | Medline18. Maruhashi, T, Kihara, Y, Higashi, Y. Bilirubin and endothelial function. J Atherosclerosis Thromb. 2019;26:688–696.
Google Scholar | Crossref | Medline19. Kühn, T, Sookthai, D, Graf, ME, et al. Albumin, bilirubin, uric acid and cancer risk: results from a prospective population-based study. Br J cancer. 2017;117:1572–1579.
Google Scholar | Crossref | Medline20. Zhu, B, Wu, X, Bi, Y, Yang, Y. Effect of bilirubin concentration on the risk of diabetic complications: a meta-analysis of epidemiologic studies. Sci Rep. 2017;7:1–15.
Google Scholar | Medline21. Zhong, K, Wang, X, Ma, X, et al. Association between serum bilirubin and asymptomatic intracranial atherosclerosis: results from a population-based study. Neurol Sci. 2020;41:1531–1538.
Google Scholar | Crossref | Medline22. Balta, S, Mikhailidis, DP, Demirkol, S, Ozturk, C, Celik, T, İyisoy, A. Endocan: a novel inflammatory indicator in cardiovascular disease. Atherosclerosis. 2015;243:339–343.
Google Scholar | Crossref | Medline | ISI23. Elena, S, Sofia, M, Teresa, VF, et al. Sex-specific differences in left ventricular mass and myocardial energetic efficiency in non-diabetic, pre-diabetic and newly diagnosed type 2 diabetic subjects. Cardiovasc Diabetol. 2021;20:60.
Google Scholar | Crossref | Medline24. Thomas, HM, Thierry, CG, Gerard, A, Julio, C. European Heart Journal – Cardiovascular Imaging. 2015;16:577–605.
Google Scholar25. Schwertner, HA, Jackson, WG, Tolan, G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem. 1994;40:18–23.
Google Scholar | Crossref | Medline | ISI26. Kimm, H, Yun, E, Jo, J, Jee, SH. Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke. 2009;40:3422–3427.
Google Scholar | Crossref | Medline | ISI27. Perlstein, TS, Pande, RL, Beckman, JA, Creager, MA. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: national health and nutrition examination survey (NHANES) 1999 to 2004. Arterioscler Thromb Vasc Biol. 2008;28:166–172.
Google Scholar | Crossref | Medline | ISI28. Novotny, L, Vitek, L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med. 2003;228:568–571.
Google Scholar | SAGE Journals | ISI29. Vítek, L . The role of bilirubin in diabetes, metabolic syndrome and cardiovascular diseases. Front Pharmacol. 2012;3:55.
Google Scholar | Crossref | Medline | ISI